Overview

Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The study will assess the efficacy of EP2006 compared to Filgrastim with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
Phase:
Phase 3
Details
Lead Sponsor:
Sandoz
Treatments:
Lenograstim